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Abstract
Background: Non-commercial clinical research plays an increasingly essential role for global health. Multiple
partners join in international consortia that operate under the limited timeframe of a specific funding period.
One organisation (the sponsor) designs and carries out the trial in collaboration with research partners, and is
ultimately responsible for the trial’s scientific, ethical, regulatory and legal aspects, while another organization,
generally in the North (the funder), provides the external funding and sets funding conditions. Even if external funding
mechanisms are key for most non-commercial research, the dependence on an external funder’s policies may heavily
influence the choices of a sponsor. In addition, the competition for accessing the available external funds is great, and
non-commercial sponsors may not be in a position to discuss or refuse standard conditions set by a funder.
To see whether the current definitions adequately address the intricacies of sponsorship in externally-funded
trials, we looked at how a “sponsor” of clinical trials is defined in selected international guidelines, with particular
focus on international Good Clinical Practices codes, and in selected European and African regulations/legislations.
Discussion: Our limited analysis suggests that the sponsors definition from the 1995 WHO Good Clinical Practices
code has been integrated as such into many legislations, guidelines and regulations, and that it is not adequate to
cover today’s reality of funding arrangements in global health, where the legal responsibility and the funding source
are de facto split. In agreement with other groups, we suggest that the international Good Clinical Practices codes
should be updated to reflect the reality of non-commercial clinical research. In particular, they should explicitly include
the distinction between commercial and non-commercial sponsors, and provide guidance to non-commercial
sponsors for negotiating with external funding agencies and other research counterparts.
Summary: Non-commercial sponsors of clinical trials should surely invest in the development of adequate
legal, administrative and management skills. By acknowledging their role and specificities, and by providing
them with adapted guidance, the international Good Clinical Practices codes would provide valuable guidance and
support to non-commercial clinical research, whose relevance for global health is increasingly evident.
Background
The North–south divide in access to health is very large.
Clinical research & development (R&D) follows a similar
pattern, and this despite rapid evolution in the field of
clinical trials in the South. There is a clear tendency to
relocate trials to resource-poor settings [1, 2], either for
reasons of external validity, i.e. to challenge findings ob-
tained in the North on new drugs and devices in a var-
iety of epidemiological settings and populations; or for
convenience reasons, represented by lower costs, less
stringent review, and potentially higher recruitment
rates; or for global health reasons, when the choice for a
location in the South is driven by the need to address
the specific health needs of the local population.
In recent years, there has been a significant increase in
clinical research carried out under non-commercial
North–south collaborations, prompted by global health
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reasons. Non-commercial clinical research as well as
public-private partnerships are essential for R&D of
medical products of no direct commercial interest, for
assessing the effectiveness and feasibility of medical
products and health interventions in specific contexts/
groups, and for providing independent evaluation of
such products and interventions [3, 4]. The increased
availability of funds and technological investment for
global health [5, 6], by philanthropic charities, founda-
tions, public-private partnerships, bilateral/multilateral
aid, and sometimes pharmaceutical companies, provide
opportunities for non-commercial research groups to
design, carry out and sponsor scientifically sound clinical
research in traditionally neglected areas, e.g. infectious
neglected diseases and tuberculosis.
In commercial research, the same organization (usu-
ally, a pharmaceutical company) funds, designs and car-
ries out a trial. But the new context of North–South
collaborations often leads to complex arrangements,
with multiple partners joining in international consortia
that often have an ad hoc structure and operate under
the limited timeframe of a specific funding period.
Only in few cases will academic sponsors be able to
conduct trials without external funding. Generally, one
agency in the North (usually a foundation or a public
authority) provides the funding and sets conditions for
such funding, and another organization (henceforward
called the sponsor), usually but not always located in the
North, designs and conducts the trial, in collaboration
with research partners. The financial arrangements be-
tween the funding agency and the research partners are
formalized in contracts defining respective roles and re-
sponsibilities, and they may be quite complex. The main
contract is usually signed between the funder and the
non-commercial research consortium, and it defines the
conditions under which the agreed funding will be dis-
bursed. The liability issues generated by the testing of
new medicines, devices or protocols should be carefully
considered in contractual agreements. The set-up of a
complex multi-institutional partnership may sometimes
be at odds with the concept of “single sponsorship“,
which was developed for ensuring the protection of par-
ticipants in the context of commercial trials. Single
sponsorship is rooted in the need to clearly identify the
legal responsibility, and does not hinge upon the “fund-
ing” aspect. Noteworthy, most funding agencies are un-
willingly to take on the role of sponsor and often they
may not be suitable for this.
Non-commercial international research is not immune
from any risks for exploitation, depending on how it is
designed and conducted and on how findings are imple-
mented and disseminated. Exploitation can arise when
the ambitions of the academic sponsors or the strategical
plans of the funders prevail on the interests of the
communities. Hence the importance to strengthen the
regulatory framework for non-commercial research,
starting with the key question on the legal responsibility.
The concept of sponsorship merits closer scrutiny in
this context. To enlighten the debate we examined how
a “sponsor” of clinical trials is defined in selected inter-
national or national guidelines and legislation, and dis-
cuss whether current definitions adequately address the
intricacies of sponsorship in externally (i.e. “outside of
the sponsor”)-funded trials.
Discussion
Among international guidelines, we considered those
that most often inspire national legislations: the Declar-
ation of Helsinki, the International Ethical Guidelines
for Biomedical Research Involving Human Subjects
(CIOMS), and the Good Clinical Practices (GCP) code
of the World Health Organization (WHO) and of the
International Conference for Harmonization (ICH).
However, the Helsinki Declaration [7] and the CIOMS
Guidelines [8] do not give a specific definition of what a
“sponsor” is nor of its duties, even if both mention
“sponsors” among the actors of medical research, and
the CIOMS Guidelines also talk of “externally sponsored
research” in relation to trials carried out in a different
host country. Therefore, the Helsinki Declaration and
the CIOMS Guidelines were excluded from the com-
parative analysis.
The selection of the international regulations and na-
tional guidelines/legislations included in the analysis was
guided by our experience in North–South collaborative
trials that bring together African and European institu-
tions. Thus, we focused on the European and African
regulatory environment. Among international regula-
tions, we considered the European Union (EU) Directive,
which is the main reference for European Member States
and funding agencies. Among national guidelines/legisla-
tion, we considered the UK Clinical Trials Regulation,
which is the main reference for some Commonwealth
countries and for UK funding agencies, and the regula-
tions/legislation of host countries of our research projects,
i.e. Belgium, South Africa, Ethiopia, Uganda and Ghana.
Sponsor’s definitions
Table 1 gives an overview of the definition of sponsor in
the selected documents. The WHO/GCP Guidelines, is-
sued in 1995 [9], define the sponsor as “an individual, a
company, an institution or an organization which takes
responsibility for the initiation, management and/or fi-
nancing of a clinical trial”. The ICH/GCP Guidelines, is-
sued in 1996 [10], use exactly the same definition, which
leaves some degree of ambiguity about whether the
sponsor should be primarily responsible for the “initi-
ation and management” of a trial, or for its “financing”,
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or for both. This definition reflects the situation of
the ‘90s, when clinical trials were mainly conducted
in Western contexts by commercial sponsors assum-
ing both roles. Both GCP codes accept the notion of
“sponsor-investigator”, which only refers to an indi-
vidual, thus is not applicable to non-commercial
sponsors in global clinical research.
The same definition was found in the South African
[11] and Ethiopian [12] GCP guidelines (where the
“funder” is mentioned but not defined), and in the 2001/
20/EC/EU Directive [13]. The definition of the EU Dir-
ective was incorporated into national legislations, such
as the Belgian Law of 2004 [14]. Noteworthy, the Belgian
Law distinguishes between commercial and non-
commercial sponsors and is explicit about the fact that
the same responsibilities hold for both, although it as-
sures some rights (such as data ownership) for non-
commercial sponsors.
However, the recent European Regulation on Clinical
Trials on Medicinal Products for Human Use [15] intro-
duced an important clarification in the definition of a
sponsor: “an individual, company, institution or organ-
isation which takes responsibility for the initiation, the
management and for setting up the financing of the clin-
ical trial”. This definition clarifies that the sponsor is
equally scientifically, legally and financially responsible
but, by replacing the wording “financing” with the
wording “setting up the financing”, it acknowledges that
the budget can either come from the sponsor itself or
from sources external to the research group. The UK
regulators had already incorporated this nuance in their
definition of sponsor, which is the one taking responsi-
bility for the initiation, management and financing (or
arranging the financing) of a trial [16].
The shift in the European legislation is in line with the
growing attention paid to non-commercial research. Pre-
viously there was a description of the features of non-
commercial clinical trials (i.e. those conducted without
the participation of the pharmaceutical industry) and of
non-commercial sponsors (i.e. universities, hospitals,
public scientific organisations, non-profit institutions,
patient organisations or individual researchers) [17]. The
new regulation is much more explicit in acknowledging
the importance of clinical trials conducted by non-
commercial sponsors, which often rely on external fund-
ing from funds or charities.
Also in Africa, we find definitions which depart from
the WHO/GCP guidelines, to be better rooted in the
current reality. The previous (2007) Uganda National
Guidelines for Research Involving Humans as Research
Participants stated that the sponsor is responsible for
providing all the necessary financial support for initi-
ation and completion of the research project, while the
detailed description of the sponsor’s responsibilities
Table 1 Overview of the definition of sponsor
Guideline/regulation Year Sponsor’s definition
WHO GCP 1995 An individual, a company, an institution or an organization which takes responsibility for the
initiation, management and/or financing of a clinical trial.
ICH GCP 1996 An individual, a company, an institution or an organization which takes responsibility for the
initiation, management and/or financing of a clinical trial.
EU Directive 2002 An individual, company, institution or organization which takes responsibility for the initiation,
management and/or financing of a clinical trial
Belgian Law 2004 An individual, company, institution or organization which takes responsibility for the initiation,
management and/or financing of a clinical trial
UK Regulation 2004 Takes responsibility for the initiation, management and financing (or arranging the financing)
of that trial.
South Africa GCP 2006 An individual, company, institution, or organisation which takes responsibility for the initiation,
management, and/or financing of a clinical trial
Uganda Guidelines 2007 The sponsor is responsible for providing all the necessary financial support for initiation and
completion of the research project
Uganda Guidelines 2014 The sponsor as such is not defined
Ghana GCP 2013 An individual, company, institution or organization which takes responsibility for the initiation,
management and/or financing of a trial. This excludes an individual company, institution or
organization which has been requested to provide money for a trial and does not benefit in any
way from the results of the trial
EU Regulation 2014 An individual, company, institution or organisation which takes responsibility for the initiation,
the management and for setting up the financing of the clinical trial
Ethiopia GCP Not dated An individual, a company, an institution or an organization which takes responsibility for the
initiation, management and/or financing of a clinical trial.
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covered the different aspects of trial initiation and man-
agement [18]. The recent new Guidelines, issued in July
2014 [19], do not include anymore a formal definition of
sponsor; however, the sponsor is still held responsible
for providing all the necessary for implementation of the
trial, including post-research obligations, while the de-
tailed description of its responsibilities still covers the
different aspects of trial initiation and management. In
the Ghana GCP code [20], a clarification was added to
the WHO/GCP definition, to clarify that an individual,
company, institution or organization that provides
money for a trial without benefiting from its results, is
excluded from the definition of sponsor. Thus, for exter-
nally funded trials, the sponsor’s legal responsibility re-
mains with the organization that initiates and manages
the trial.
Sponsor versus funder
This analysis suggests that the WHO/GCP definition of
sponsor has been integrated as such into many inter-
national and national legislations, guidelines and regula-
tions, and is not entirely adequate to cover the reality of
funding arrangements in global health today (even if the
difference between commercial and non-commercial
sponsors is sometimes acknowledged). Some guidelines
(South Africa, Ethiopia) mention the “funder” in
addition to the sponsor, and some others (UK, Ghana,
EU) reflect the fact that two or more different entities
may respectively initiate/conduct a trial, and (co-)finance
it. The former entity is the legal sponsor, while the latter
is the external funder. But some ambiguity remains be-
tween “sponsor” and “funding agency”. This was further
confirmed by the unsatisfactorily results of a comple-
mentary literature search: the wording “sponsor” was
often inaccurately referred to as the organization that
funds a research, i.e. in a “lay” meaning (like for the
“sponsor” of an event), rather than in the GCP meaning.
This ambiguity may contribute to the poor awareness
of some inexperienced sponsors, especially in the
non-commercial sector, of the scope of their own
responsibilities.
The legal sponsor is ultimately responsible for the sci-
entific, ethical, regulatory and legal aspects of the trial,
and also for financial aspects (i.e., if an external funder
withdraws, the sponsor will be responsible to look for
funds to complete the trial). It is therefore its primary
role and responsibility to ensure that sufficient resources
are planned for full compliance with ethical and GCP re-
quirements. Sponsors’ poor awareness of such require-
ments, which are described more in details in Table 2,
may lead to underestimation of the overall study budget.
In the specific case of externally-funded research, this
will lead them to requesting insufficient financial re-
sources from the funding agency.
Non-commercial sponsors often face budgetary prob-
lems because of the poor flexibility of the external fund-
ing [21, 22]. Some funding bodies will not accept a
miscellaneous budget line for contingency/incidentals
and are unwilling to review or supplement the budget
once agreements have been finalized (which often hap-
pens before detailed protocols have been developed, and
even before the clinical sites’ needs are thoroughly
assessed). The lack of flexibility is problematic also in
other situations [23], e.g. when recruitment is slower
than anticipated because of reasons beyond control of
investigators, or when exchange rate with the local cur-
rency fluctuates over time: for instance, depreciation will
make it more difficult to buy equipments abroad, while
appreciation will decrease the local value of foreign
funds.
As mentioned above, the poor awareness of GCP re-
quirements may lead sponsors to requesting insufficient
financial resources from the funding agency. But in
other cases the budget awarded by the funding agency is
much lower than the initially requested one, and may be
insufficient to meet all costs required for full GCP-
compliance, e.g. adequate external monitoring or data
management set-up, costs that are unfortunately often
the first to be cut in such situation.
Negotiations between non-commercial sponsors and funders
One could argue that it is the sponsor’s responsibility to
ensure that adequate funding and funding’s conditions are
negotiated for carrying out a trial according to appropriate
standards, and to reject unsatisfactory conditions. Even
though some sponsors underestimate the budget, in real-
ity many cost items may be impossible to foresee in ad-
vance [22]. Awareness of GCP-requirements and good
negotiation skills are both essential to ensure that the po-
sitions of the funding agency and the research consortium
are sufficiently reflected in the final contract, but in prac-
tice, contracts are often based on the standard templates
of the funding agency. Many non-commercial sponsors
lack a legal department with enough human resources to
conduct such negotiations. According to an analysis of the
Council in Health Research for Development (COHRED),
for instance, various research institutions in Africa and
Asia have weak contracting capacity [24]. In addition,
non-commercial sponsors often find themselves in a pos-
ition of power unbalance vis-à-vis the funding agency.
The competition for accessing the external funds available
for health research is great, and most North- or South-
based non-commercial sponsors may not be in a position
to negotiate the rules set by the funding agencies. They
have to balance the risk of a contract that does not reflect
particular quality requirements (“contractual risk”) versus
the risk of being unable to conduct research relevant for a
given population (“ethical risk”).
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The way forward?
In externally-funded clinical research, the legal responsi-
bility and the funding source are often de facto split.
The liability risks of sponsors, as well as those of re-
searchers and other research actors have been described
[25]. However, to our knowledge the responsibilities of
the funding agencies have not been described so far,
even if in non-commercial research many choices may
be positively or negatively influenced/determined by
their policy.
Some guidelines are subject to periodical update,
which allows taking new challenges into account. An
example of this dynamic is given by the revision of
the Helsinki Declaration, preceded by a public debate.
Conversely, the WHO/ and ICH/GCP Guidelines,
which orient most national legislators, were issued re-
spectively in 1995 and 1996 and never updated. A re-
vision is urgently needed, to better reflect the current
reality of clinical trials including the perspective of
non-commercial research [23, 26]. More in particular,
we are not aware of any processes for the update of
the WHO/GCP. Concerning the ICH/GCP, an “Inte-
grated addendum” was published on 11th June 2015,
with the objective to”modernize the ICH E6 Guideline
by supplementing with additional recommendations
which will facilitate broad and consistent international
implementation of new methodologies”. This draft
text, now transmitted to the National Regulatory Au-
thorities of the ICH region for internal and external
consultation (accessed on 27th August 2015 at http://
www.ich.org/products/guidelines/efficacy/efficacy-sin-
gle/article/addendum-good-clinical-practice.html), does
not address the definition of sponsor.
We suggest in the first place that the international
GCP codes should include the distinction between com-
mercial and non-commercial sponsors.
Non-commercial sponsors should pay special attention
to the research legal framework and try to improve the
contractual agreements with the funding agency, so that
responsibilities and liability issues are fairly shared, and
other important aspects are duly clarified. To be able to
do so, non-commercial organisations that wish to act as
sponsor in clinical trials should invest in the develop-
ment of adequate legal, administrative and management
skills, just as they do for scientific skills. This would also
enable them to negotiate fair and meaningful contracts
for other key-activities in clinical research, such as the
supply of investigational products, the transfer and
Table 2 Overview of sponsor’s specific responsibilities in the international GCP codes
WHO GCP 1995 ICH GCP 1996
5.1 Selection of the Investigator(s) 5.1 Quality Assurance and Quality Control
5.2 Delegation of responsibilities 5.2 Contract Research Organization
5.3 Compliance with the protocol and procedures 5.3 Medical Expertise
5.4 Product information 5.4 Trial Design
5.5 Safety information 5.5 Trial Management, Data Handling, and Record Keeping
5.6 Investigational product 5.6 Investigator Selection
5.7 Trial management and handling of data 5.7 Allocation of Responsibilities
5.8 Standard operating procedures 5.8 Compensation to Subjects and Investigators
5.9 Compensation for subjects and investigators 5.9 Financing
5.10 Monitoring 5.10 Notification/Submission to Regulatory Authority(ies)
5.11 Quality assurance 5.11 Confirmation of Review by IRB/IEC
5.12 Study reports 5.12 Information on Investigational Product(s) (IPs)
5.13 Handling of adverse events 5.13 Manufacturing, Packaging, Labelling, and Coding IP(s)
5.14 Termination of the trial 5.14 Supplying and Handling IP(s)
5.15 Record Access
5.16 Safety Information
5.17 Adverse Drug Reaction Reporting
5.18 Monitoring
5.19 Audit
5.20 Noncompliance
5.21 Premature Termination or Suspension of a Trial
5.22 Clinical Trial/Study Reports
5.23 Multicenter Trials
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sharing of trials’ data and samples, and the policy insur-
ance contract(s) [24]. To help cope with this, we suggest
that the WHO/ and ICH/GCP Guidelines include as an-
nexes some adapted model contract templates or stand-
ard checklists, with clauses for “reasonable flexibility”, to
guide the negotiation with external funding agencies.
The same applies to templates and guidance for negoti-
ation with other research counterparts, e.g. insurance
policies, data and material transfer agreements etc.
Limitations of this analysis
Our analysis is meant to launch a debate aiming at bet-
ter legislation on non-commercial sponsorships, based
on the analysis of a sample of guidelines, laws and reg-
ulations. The international regulations and national
guidelines/legislations included in this analysis were se-
lected with focus on the European and (English-speaking)
African regulatory environment. This led to exclusion of
other influential guidelines and legislations, such as the
ones from the United States, India, and Brazil, so more re-
search is needed to investigate this issue in more regula-
tory environments.
While focusing on the sponsor’s definition and role,
we did not look at the complex dynamics that may exist
within North–South research consortia, or at the pos-
sible power unbalance between Northern and Southern
partners. As noted by Hoekman and colleagues, despite
the increasing globalization of clinical trials, the scien-
tific leadership of research tends to remain rooted in the
North [27], which may be translated into unfair benefit
sharing with local researchers, institutions and commu-
nities in the South. This phenomenon should be investi-
gated more in-depth in its own right.
Conclusion
The current definitions of “sponsor” in clinical research
do not reflect the challenges met by non-commercial
sponsors in externally-funded research, especially but
not only in the South, and in particular they do not ad-
equately cover the reality of funding arrangements in
clinical research in a global health context today. A revi-
sion of the WHO/ and ICH/GCP Guidelines is needed,
to better reflect the current reality of independent clin-
ical research.
By acknowledging the role and specificities of non-
commercial sponsors, and by providing adapted guid-
ance on standard research contracts, the international
GCP codes would provide valuable guidance and sup-
port to non-commercial clinical research, whose rele-
vance for global health is increasingly evident. This
will only succeed if representatives of institutions in-
volved in non-commercial clinical trials in the North
and in the South (researchers, sponsors, administra-
tors, legal experts etc.) are actively involved in the
next, and increasingly urgent, GCP revision. It is of crucial
importance that this review process is as inclusive, repre-
sentative and transparent as possible.
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